SAN DIEGO--(BUSINESS WIRE)--Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that Roche has selected a fifth exclusive target under the existing license and collaboration agreement. Under the terms of the agreement, Roche will pay Halozyme $4.25 million, which is net of previously paid maintenance fees, for exclusive, global rights for the application of its hyaluronidase enzyme, rHuPH20, to a fifth biologic target.